Free Trial

Exact Sciences (EXAS) Stock Forecast & Price Target

$46.81
-0.75 (-1.58%)
(As of 07/19/2024 ET)

Exact Sciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 15 Wall Street analysts who have issued ratings for Exact Sciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a hold rating, and 14 have given a buy rating for EXAS.

Consensus Price Target

$85.80
83.29% Upside
High Forecast$121.00
Average Forecast$85.80
Low Forecast$70.00

According to the 15 analysts' twelve-month price targets for Exact Sciences, the average price target is $85.80. The highest price target for EXAS is $121.00, while the lowest price target for EXAS is $70.00. The average price target represents a forecasted upside of 83.29% from the current price of $46.81.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$85.80$93.07$97.44$88.89
Forecasted Upside83.29% Upside32.15% Upside27.81% Upside28.25% Upside
Get Exact Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

EXAS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EXAS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Exact Sciences Stock vs. The Competition

TypeExact SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.93
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside83.29% Upside1,426.49% Upside10.01% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/17/2024The Goldman Sachs Group
2 of 5 stars
 Lower TargetBuy ➝ Buy$88.00 ➝ $75.00+52.07%
7/2/2024Evercore ISI
2 of 5 stars
V. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$80.00 ➝ $72.00+67.91%
6/27/2024Scotiabank
5 of 5 stars
S. Nam
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$70.00+58.51%
6/26/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$80.00 ➝ $70.00+69.20%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$75.00+67.19%
5/9/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$90.00 ➝ $85.00+55.25%
5/9/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$100.00 ➝ $80.00+47.17%
2/22/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
1/2/2024Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$91.00+23.01%
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$90.00+32.92%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$95.00+44.99%
10/16/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$90.00 ➝ $80.00+19.67%
9/28/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$83.00+23.04%
8/2/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$105.00 ➝ $110.00+14.06%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$75.00 ➝ $90.00-6.68%
8/2/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$99.00 ➝ $121.00+25.47%
6/22/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$85.00 ➝ $120.00+26.25%
6/22/2023Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$85.00 ➝ $106.00+18.07%
5/5/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$73.00+10.96%
2/22/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$56.00 ➝ $76.00+24.06%
1/18/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
1/12/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$70.00 ➝ $75.00+9.59%
8/3/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$83.00 ➝ $67.00+40.37%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:17 AM ET.

EXAS Forecast - Frequently Asked Questions

What is Exact Sciences' forecast for 2024?

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Exact Sciences is $85.80, with a high forecast of $121.00 and a low forecast of $70.00.

Should I buy or sell Exact Sciences stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There is currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EXAS shares.

Does Exact Sciences's stock price have much upside?

According to analysts, Exact Sciences's stock has a predicted upside of 36.07% based on their 12-month stock forecasts.

What analysts cover Exact Sciences?

Exact Sciences has been rated by research analysts at BTIG Research, Canaccord Genuity Group, Citigroup, Evercore ISI, Jefferies Financial Group, Scotiabank, and The Goldman Sachs Group in the past 90 days.

Do Wall Street analysts like Exact Sciences more than its competitors?

Analysts like Exact Sciences more than other "medical" companies. The consensus rating score for Exact Sciences is 2.93 while the average consensus rating score for "medical" companies is 2.72. Learn more on how EXAS compares to other companies.


This page (NASDAQ:EXAS) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners